• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
YPB
Click for more information
0.00% 0.2¢

YPB GROUP LTD - Charts / Financials

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

YPB Group Limited (ASX:YPB) develops and sells a suite of product authentication and... YPB Group Limited (ASX:YPB) develops and sells a suite of product authentication and consumer engagement technologies designed for a world where authenticity triggers engagement, and the value of consented first-party data is ever increasing.More

refresh Created with Sketch. REFRESH
Day
Open 0.2¢   Day High 0.2¢   Day Low 0.2¢
Daily Volume 1386216
Bids   Sellers
Number Price Volume   Number Price Volume
11 0.2¢ 12355763   20 0.3¢ 10400827

Directors & Senior Management

Mr. John Houston Executive Chairman of the Board
Mr. Adrian Tan Chief Financial Officer
Ms. Shelby Coleman Joint Company Secretary
Mrs. Lucy Rowe Company Secretary
Mr. Gerard Eakin Independent Non-Executive Director
Mr. Su Su Independent Non-Executive Director

Data source: Refinitiv

Top Stories

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.